🔜 #ELCC26 @myesmo.bsky.social
🔥Adaptive escalation and de-escalation treatment for NSCLC
☑️ #Biomarker #DeEscalation #Escalation #TrialDesign
🎙️Chair: Dr. Stephanie Saw Dr. Jordi Remon
@oncoalert.bsky.social LARVOL #LCSM

Advocates describe multi‑stakeholder platforms — Accelerate and MIB agents — that shape pediatric and osteosarcoma research Advocacy groups and young patient leaders described how multi‑stakeholder platforms (Accelerate) and nonprofit programs (MIB agents) bring patients, clinicians, industry and regulators together to set priorities, run strategy forums, and create mentorship and research funding that influence trial design and policy.

Patient advocates are revolutionizing pediatric and rare cancer research by uniting voices from all corners of the healthcare spectrum to prioritize patient needs and improve trial designs.

Learn more here

#US #PediatricOncology #CitizenPortal #PatientAdvocacy #TrialDesign #ResearchInnovation

Copy of an 8 year old Twitter/Facebook post saying "The most fanstastic clinical trial design ever? The worst devaluation of randomization!" and then the cited reference is: "the design is dynamic, prospective, quasi-experimental with no control group cohort study" in the journal Rev. Soc. Esp. Dolor 2017; 24:4 (201-210)

Still the worst devaluation of randomization I have ever come across. #stats #trialdesign #experimentaldesign #mumbojumbo

From a Standard to Platform Approach: The Next Wave of Glomerular Disease Clinical Trials | Docwire News Vlado Perkovic discussed glomerular disease clinical trial design, including basket, umbrella, platform, and pragmatic trials, at GlomCon Hawaii 2025.

Vlado Perkovic shared his thoughts on glomerular disease clinical trial design, a topic on which he presented at #GlomConHawaii. #trialdesign #kidneydisease #glomerulardisease #nephrology #nephsky docwirenews.com/post/from-a-...

FDA targets innovative CGT trial designs in draft guidance The draft guidance sets out six alternative trial designs that sponsors could adopt in CGT studies, as well as guidance on endpoints and patient selection.

FDA targets innovative CGT trial designs in draft guidance - buff.ly/ZfV7kza #clinicaltrial #clinicaltrials #trialdesign #guidance #fda

Doctor visit frequency can shape your entire commercial model.

Touchpoints = time to test, diagnose, and treat.

In the US? 3 visits

South Korea? 16 visits

👉 Start your strategy there.

#HealthData #DrugLaunch #TrialDesign #KIRIAResearch #HealthCare #HealthCareData

Is anyone aware of any #RCT that demonstrated the efficacy of any intervention in any CVD on the primary #endpoint of “days alive and out of the hospital”?

If so, please share.

(And what #breakfast are you having to fuel the clinical workday?)

#DAOH #TrialDesign

The Design of a Randomized Controlled Active Comparator Strategy Trial for Gout: Treat to Target Serum Urate Versus Treat to Avoid Symptoms. Graphical abstract created with BioRender.

Randomized controlled active comparator strategy trial is proposed to address whether treating to a target serum urate vs treating to avoid symptoms is more effective for optimal management of gout

ACR Open Rheumatology
doi.org/10.1002/acr2...
#Medsky #Rheumsky #trialdesign #gout

Leveraging Technology for Efficient Trial Design Teams must work together with technology solutions and optimize integration to unlock their full potential.

Leveraging Technology for Efficient Trial Design - buff.ly/o6dzCvC #clinicaltrial #clinicaltrials #trialdesign #technology

This morning one of my participant advisors called just to say “hi” and gave me a few words of encouragement and wisdom. And just a few hours later I got the go-ahead for a new research proposal! Participant support gives you power! #endalz #participantfeedback #trialdesign

Designing and optimizing clinical trials for long COVID Long COVID is a debilitating, multisystemic illness following a SARS-CoV-2 infection whose duration may be indefinite. Over four years into the pandem…

Link to research mentioned in the thread above:

Designing and optimizing clinical trials for long COVID - ScienceDirect
www.sciencedirect.com/science/arti...

#Covid #LongCovid #ClinicalTrial #TrialDesign #PatientLed

Thread by @patientled on Thread Reader App @patientled: We’ve released a new paper on designing & optimizing clinical trials for #LongCOVID! Strong, high-impact trials are critical & most current ones are insufficient. The paper gives guidance...

From @patientled.bsky.social (on Twitter):
"We’ve released a new paper on designing & optimizing clinical trials for #LongCOVID! Strong, high-impact trials are critical & most..."
threadreaderapp.com/thread/18267...

#Covid #LongCovid #ClinicalTrial #TrialDesign #PatientLed

Non-Inferiority Trials in Medicine: Practice Changing or ...

#MedEd #GrainOfSalt #trialdesign #outcomes
Non-inferiority trials... an inferior RCT structure?

@amtejani
@Drug_Evidence
@AKECassels link.springer.com/article/10.1007/s11606-0...